Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
A Phase 4, Open-label, Multicentre, 2-Year Safety Study of Lisdexamfetamine in Children and Adolescents with ADHD
2010-020951-30Phase 4Completed
- Sponsor
- Takeda
- Start
- Oct 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of lisdexamfetamine in attention deficit hyperactivity disorder (ADHD), sponsored by Takeda. Primary endpoint: Primary safety endpoint. Started Oct 2010; status: completed.
02
Drugs
lisdexamfetamine
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on 2010-020951-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-020951-30.